ZYME

Note: The filing text does not provide specific gross margin or operating margin percentages.

Material Changes vs. Prior Period

• Revenue Composition: Revenue remained relatively flat year-over-year ($76.3M vs $76.0M). However, the mix shifted significantly. In 2024, the company recognized $25.0 million in milestone revenue from Jazz Pharmaceuticals following the FDA approval of Ziihera and $8.0 million from BeiGene for the acceptance of the BLA in China. This was partially offset by a decrease in development support revenue from Jazz due to the transfer of program responsibilities.
• Expense Reductions: R&D expenses decreased by $9.0 million, primarily driven by reduced costs for the zanidatamab program (transferred to Jazz) and the completion of IND-enabling studies for ZW171 and ZW191. G&A expenses decreased by $8.9 million due to lower external consulting and legal fees.
• Impairment Charge: The company recorded a one-time $17.3 million impairment charge on acquired in-process research and development (IPR&D) assets related to the decision to discontinue the zanidatamab zovodotin clinical development program.
• Liquidity: Cash and marketable securities decreased by approximately $132 million year-over-year, reflecting operating cash outflows and a $30.1 million stock repurchase program.

Guidance, Outlook, and Risks

Outlook and Pipeline:

• Zanidatamab (Ziihera): Initial U.S. sales began in December 2024. The company expects to report outcomes of pending regulatory actions in the EU and China in 2Q-2025. Top-line data from the HERIZON-GEA-01 study (gastroesophageal adenocarcinoma) is expected in 2H-2025.
• Wholly-Owned Pipeline: The company is advancing its "5 by 5" solid tumor strategy. Phase 1 trials for ZW191 (FRα-targeting ADC) and ZW171 (MSLN-targeting TCE) are ongoing. The company plans to submit an IND for ZW251 (GPC3-targeting ADC for HCC) by mid-2025. Preparations for ZW220 have been paused to prioritize ZW251.
• AIID Expansion: ZW1528, a bispecific for respiratory inflammation (COPD), is nominated for development with an expected IND submission in 2H-2026.

Capital Resources:

• Management anticipates that existing cash resources ($324.2 million) will fund operations for at least the next 12 months.
• The company has a $60.0 million share repurchase program; as of December 31, 2024, $30.0 million remained available.

Key Risks:

• Regulatory Dependence: Continued approval of Ziihera is contingent on the successful completion of a confirmatory trial. Failure could result in market withdrawal.
• Partnership Reliance: Future revenue depends heavily on Jazz and BeiGene achieving milestones and commercializing Ziihera.
• Profitability: The company has a history of significant losses and does not anticipate regular net income in the foreseeable future.
• Intellectual Property: Risks related to patent challenges and the ability to enforce IP rights globally.

Investor Verification Checklist

• Confirmatory Trial Status: Verify the progress and design of the Phase 3 HERIZON-BTC-302 confirmatory trial required to maintain Ziihera's accelerated approval.
• Commercial Uptake: Monitor early sales data and royalty accruals from Jazz Pharmaceuticals following the December 2024 launch.
• Regulatory Decisions: Track the expected 2Q-2025 decisions from the EMA (Europe) and NMPA (China) regarding zanidatamab.
• Pipeline Milestones: Confirm the timing of the IND submission for ZW251 (mid-2025) and the top-line data release for HERIZON-GEA-01 (2H-2025).
• Cash Burn Rate: Assess whether the $324.2 million cash balance is sufficient to fund the expanded pipeline and operations beyond the 12-month runway without further dilution.